Results 151 to 160 of about 6,870,828 (229)

The Urokinase-Type Plasminogen Activator Receptor (uPAR) as a Mediator of Physiological and Pathological Processes: Potential Therapeutic Strategies. [PDF]

Cancers (Basel)
Iftikhar A, Mahmood N, Rabbani SA.
europepmc   +1 more source

Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma. [PDF]

J Gastrointest Oncol, 2023
Wu J, Sun M, Li Z, Shen Y, Wu Y, Zhang H, Xu Z, Gao Q.   +7 more
europepmc   +1 more source

Transcriptomic Profiling Reveals Urokinase-Type Plasminogen Activator-Mediated Regulation of Metabolic Competence and Cumulus Expansion During Mouse Oocyte In Vitro Maturation. [PDF]

Int J Mol Sci
Yeh LY, Chiu CS, Lee KS, Lee RK, Lin MH, Hwu YM, Li SH.   +6 more
europepmc   +1 more source

Association between Serum Soluble Urokinase-Type Plasminogen Activator Receptor Level and Arterial Stiffness in Chronic Hemodialysis Patients. [PDF]

J Pers Med, 2023
Lin WC, Wu TJ, Wang CH, Hsieh YJ, Hsu BG.   +4 more
europepmc   +1 more source

Elevated Soluble Urokinase-Type Plasminogen Activator Receptor Levels, Organ Dysfunction, and Death in Children Hospitalized With Malaria: Considerations for Use as a Risk Stratification Tool. [PDF]

J Infect Dis
Ssuuna C, Mishra H, Hawkes MT, Stefanova V, Leligdowicz A, Lintner-Rivera M, Batte A, Zhong K, Namasopo S, Opoka RO, Kain KC, Conroy AL.   +11 more
europepmc   +1 more source

Role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: A systematic review and meta analysis. [PDF]

Medicine (Baltimore), 2023
Rehan ST, Hussain HU, Ali E, Kumar KA, Tabassum S, Hasanain M, Shaikh A, Ali G, Yousaf Z, Asghar MS.   +9 more
europepmc   +1 more source

Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) and Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) for Biochemical Recurrence After Radical Prostatectomy. [PDF]

Med Sci Monit
Wang H, Huang C.
europepmc   +1 more source

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. [PDF]

J Transl Med, 2022
Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ, Fan Y, Guo DY.   +8 more
europepmc   +1 more source

Virus-derived serpin reduces immuno-coagulopathic damage in murine colitis by targeting the urokinase-type plasminogen activator receptor (uPAR) and complement. [PDF]

Sci Rep
Lucas AR, Monder H, Enow J, Woodrow C, Spaccarelli L, Garg A, Schlievert J, Elmadbouly N, Dupati A, Aliskevich E, Saju R, Kilbourne J, Lowe K, Hamada M, Pinteric A, Zanetti IR, Satyanarayanan RS, Gisriel S, Florsheim EB, Rahman M, Irving J, McFadden G, Kong W, Zhang L.   +23 more
europepmc   +1 more source

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors [PDF]

The Journal of cell biology, 1987
Blasi, F., Vassalli, Jean-Dominique, Dano, K.   +2 more
openaire   +3 more sources